Patents by Inventor Yuuki Takaishi

Yuuki Takaishi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulations of enzalutamide
    Patent number: 11839689
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: December 12, 2023
    Assignees: Astellas Pharma Inc., Medivation Prostate Therapeutics LLC
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • Pharmaceutical composition for modified release
    Patent number: 11707451
    Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: July 25, 2023
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yuuki Takaishi, Soichiro Nakamura, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Kazuhiro Sako
  • Formulations of Enzalutamide
    Publication number: 20230210778
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: November 11, 2022
    Publication date: July 6, 2023
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20230122911
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: November 11, 2022
    Publication date: April 20, 2023
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • LIQUID CRYSTAL POLYMER COMPOSITION, LIQUID CRYSTAL POLYMER MOLDED BODY, AND CAMERA MODULE
    Publication number: 20220380675
    Abstract: Provided is a liquid crystal polymer composition having a low coefficient of static friction and a low coefficient of kinetic friction both during sliding between a liquid crystal polymer molded body and a metallic material and during sliding between liquid crystal polymer molded bodies. The liquid crystal polymer composition contains a liquid crystal polymer (A), a polytetrafluoroethylene resin (B), and barium sulfate (C).
    Type: Application
    Filed: December 3, 2020
    Publication date: December 1, 2022
    Applicant: OTSUKA CHEMICAL CO., LTD.
    Inventors: Toshihiro Maruo, Yuuki Takaishi
  • PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE
    Publication number: 20210322387
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25 C is disclosed.
    Type: Application
    Filed: November 19, 2020
    Publication date: October 21, 2021
    Inventors: YUUKI TAKAISHI, YUTAKA TAKAHASHI, TAKASHI NISHIZATO, DAISUKE MURAYAMA, EMIKO MURAYAMA, SOICHIRO NAKAMURA, KAZUHIRO SAKO
  • PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE
    Publication number: 20210085654
    Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.
    Type: Application
    Filed: December 8, 2020
    Publication date: March 25, 2021
    Inventors: YUUKI TAKAISHI, SOICHIRO NAKAMURA, YUTAKA TAKAHASHI, TAKASHI NISHIZATO, DAISUKE MURAYAMA, EMIKO MURAYAMA, KAZUHIRO SAKO
  • Pharmaceutical composition for modified release
    Patent number: 10842780
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: November 24, 2020
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yuuki Takaishi, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Soichiro Nakamura, Kazuhiro Sako
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20200060976
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: April 1, 2019
    Publication date: February 27, 2020
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20190209476
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: July 24, 2018
    Publication date: July 11, 2019
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE
    Publication number: 20170231965
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.
    Type: Application
    Filed: February 14, 2017
    Publication date: August 17, 2017
    Applicant: ASTELLAS PHARMA INC.
    Inventors: YUUKI TAKAISHI, YUTAKA TAKAHASHI, TAKASHI NISHIZATO, DAISUKE MURAYAMA, EMIKO MURAYAMA, SOICHIRO NAKAMURA, KAZUHIRO SAKO
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20170224624
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: September 16, 2016
    Publication date: August 10, 2017
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20170027910
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: February 8, 2016
    Publication date: February 2, 2017
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • PHARMACEUTICAL COMPOSITION FOR MODIFIED USE
    Publication number: 20160184275
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.
    Type: Application
    Filed: September 28, 2009
    Publication date: June 30, 2016
    Applicant: ASTELLAS PHARMA INC.
    Inventors: YUUKI TAKAISHI, YUTAKA TAKAHASHI, TAKASHI NISHIZATO, DAISUKE MURAYAMA, EMIKO MURAYAMA, SOICHIRO NAKAMURA, KAZUHIRO SAKO
  • PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE
    Publication number: 20150126565
    Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.
    Type: Application
    Filed: December 29, 2014
    Publication date: May 7, 2015
    Inventors: YUUKI TAKAISHI, SOICHIRO NAKAMURA, YUTAKA TAKAHASHI
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20140378517
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: September 10, 2014
    Publication date: December 25, 2014
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • Pharmaceutical composition for modified release
    Patent number: 8877214
    Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of the drug from the composition is less than 85% after 30 minutes from the beginning of a dissolution test, is disclosed.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: November 4, 2014
    Assignee: Astellas Pharma Inc.
    Inventors: Yuuki Takaishi, Soichiro Nakamura
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20140179749
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: September 11, 2013
    Publication date: June 26, 2014
    Applicants: BEND RESEARCH, ASTELLAS PHARMA INC., MEDIVATION PROSTATE THERAPEUTICS, INC.
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20140100256
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: September 11, 2013
    Publication date: April 10, 2014
    Applicants: BEND RESEARCH, ASTELLAS PHARMA INC., MEDIVATION PROSTATE THERAPEUTICS, INC.
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE
    Publication number: 20120070465
    Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.
    Type: Application
    Filed: March 28, 2011
    Publication date: March 22, 2012
    Applicant: Astellas Pharma Inc.
    Inventors: Yuuki Takaishi, Soichiro Nakamura, Yutaka Takahashi